Home Awareness CHMP Grants Favorable Opinion: Bristol Myers Melanoma
Awareness

CHMP Grants Favorable Opinion: Bristol Myers Melanoma

Bristol Myers Squibb announces that the European Medicines Agency’s CHMP has recommended approval of Opdivo as an adjuvant therapy for patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

This positive opinion is based on safety and efficacy results from the Phase 3 CheckMate -76K trial, in which, with a minimum follow-up of 7.8 months, Opdivo reduced the risk of recurrence or death by 58% compared to placebo.

These results were presented at the 2022 annual meeting of the Society for Melanoma Research (SMR). The European Commission, which has the power to approve medicines in the European Union, will now review the CHMP recommendation.

This article is originally published on boursorama.com

Related Articles

Awareness

EU Unveils Ambitious Black Sea Strategy to Secure Post-War Ukraine and Regional Stability

The European Union has unveiled a sweeping new strategy aimed at securing...

Awareness

Council of Europe’s “Journalists Matter” Campaign Boosts Press Freedom

In response to the alarming rise in violence, threats, and legal harassment...

Awareness

One Million Europeans Urge EU Ban on Conversion Therapy

On May 17, 2025, the International Day Against Homophobia, more than one...

Awareness

Samsung Showcases Auracast Audio at St Paul’s for Accessibility Awareness

Samsung Electronics marked Global Accessibility Awareness Day 2025 with a powerful message...